Clinical Recommendations for the Use of Recombinant Human Erythropoietin in Patients with Hepatitis C Virus Being Treated with Ribavirin

Clinical Recommendations for the Use of Recombinant Human Erythropoietin in Patients with Hepatitis C Virus Being Treated with Ribavirin

Today, combination antiviral therapy with pegylated interferon-alpha and ribavirin (RBV) allows many patients infected with hepatitis C virus (HCV) to achieve a sustained virological response, which is equivalent to cure. Data also support the clinical benefit of combination antiviral therapy in pat...

Full description

Saved in:
Bibliographic Details
Main Authors: Morris Sherman, Lawrence Cohen, Mary Anne Cooper, Magdy Elkashab, Victor Feinman, David Fletcher, Nigel Girgrah, Jenny Heathcote, Mark Levstik, William B McNaull, David Wong, Florence Wong, Colina Yim
Format: Article
Language:English
Published: Wiley 2006-01-01
Series:Canadian Journal of Gastroenterology
Online Access:http://dx.doi.org/10.1155/2006/497059
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Today, combination antiviral therapy with pegylated interferon-alpha and ribavirin (RBV) allows many patients infected with hepatitis C virus (HCV) to achieve a sustained virological response, which is equivalent to cure. Data also support the clinical benefit of combination antiviral therapy in patients coinfected with HCV and HIV, and in patients who have received a liver transplant.
ISSN:0835-7900

Similar Items